Anat O. Stemmer-Rachamimov, MD, University of Milan
Affiliations: | Pathology | Masssachusetts General Hospital, Boston, MA, United States |
Area:
Heredetary Brain Tumor Syndrome, NeuropathologyOphthalmic Pathology, SurgicalsWebsite:
http://www.massgeneral.org/doctors/doctor.aspx?id=17876Google:
"Anat Stemmer-Rachamimov"Bio:
http://www.dfhcc.harvard.edu/membership/profile/member/1151/0/
Mean distance: 16.47 (cluster 24) | S | N | B | C | P |
Cross-listing: Neuropathology Tree
Parents
Sign in to add mentor| E. Tessa Hedley-Whyte | post-doc | 1999-2000 | Harvard Medical School and Masssachusetts General Hospital |
| David N. Louis | post-doc | 1999-2001 | Harvard Medical School and Masssachusetts General Hospital |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Staedtke V, Topilko P, Le LQ, et al. (2023) Existing and Developing Preclinical Models for Neurofibromatosis Type 1-Related Cutaneous Neurofibromas. The Journal of Investigative Dermatology |
| Prabhakar S, Beauchamp RL, Cheah PS, et al. (2022) Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy. Methods & Clinical Development. 26: 169-180 |
| Freeman SS, Sade-Feldman M, Kim J, et al. (2022) Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Reports. Medicine. 3: 100500 |
| Chang LS, Oblinger JL, Smith AE, et al. (2021) Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. Plos One. 16: e0252048 |
| Li M, Li G, Kiyokawa J, et al. (2020) Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathologica Communications. 8: 221 |
| Richardson LG, Nieman LT, Stemmer-Rachamimov AO, et al. (2020) IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice. Oncoimmunology. 9: 1806662 |
| Ortonne N, Carroll SL, Rodriguez FJ, et al. (2020) Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass. Neuro-Oncology Advances. 2: i117-i123 |
| Freeman SS, Sade-Feldman M, Kim J, et al. (2020) Abstract 6670: Combined signals from tumor and immune cells predict outcomes of checkpoint inhibition in melanoma Immunology. 80: 6670-6670 |
| Prabhakar S, Cheah PS, Zhang X, et al. (2019) Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy. Methods & Clinical Development. 15: 18-26 |
| Sagers JE, Sahin MI, Moon I, et al. (2019) NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss. Hearing Research. 381: 107770 |